{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:03:42Z","timestamp":1784963022338,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105574","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:48:36Z","timestamp":1756986516000},"page":"105574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study"],"prefix":"10.1016","volume":"10","author":[{"given":"H.","family":"Sakaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Furugaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yoshiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105574_bib1","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3580","article-title":"Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology","volume":"13","author":"Hallberg","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2025.105574_bib3","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-07-6186","article-title":"Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors","volume":"68","author":"McDermott","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105574_bib4","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105574_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105574_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105574_bib7","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.105574_bib10","doi-asserted-by":"crossref","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","article-title":"Crizotinib resistance: implications for therapeutic strategies","volume":"27","author":"Dagogo-Jack","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105574_bib12","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105574_bib13","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.3747\/co.25.3760","article-title":"ALK inhibitors, resistance development, clinical trials","volume":"25","author":"Rothenstein","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib14","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-20-2853","article-title":"Proteasome inhibition overcomes ALK-TKI resistance in ALK-rearranged\/TP53-mutant NSCLC via noxa expression","volume":"27","author":"Tanimoto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105574_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ijc.32133","article-title":"Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3,000 Heidelberg cases","volume":"145","author":"Volckmar","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2025.105574_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/cas.14697","article-title":"Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer","volume":"112","author":"Chin","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2025.105574_bib17","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/cas.15304","article-title":"Serial circulating tumor DNA monitoring of CDK4\/6 inhibitors response in metastatic breast cancer","volume":"113","author":"Chin","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2025.105574_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2019.10.015","article-title":"ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-positive NSCLC: pooled analysis of two prospective trials","volume":"15","author":"No\u00e9","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib19","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.annonc.2023.02.012","article-title":"Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial","volume":"34","author":"Remon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib21","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-22-0258","article-title":"Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of patients with advanced non-small cell lung cancer","volume":"2","author":"Frank","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.esmoop.2025.105574_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2025.105574_bib24","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/JTO.0000000000000113","article-title":"Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?","volume":"9","author":"Gouji","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2020.05.018","article-title":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer","volume":"146","author":"Shi","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2025.105574_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/bjc.2011.586","article-title":"Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells","volume":"106","author":"Tanizaki","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105574_bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtho.2016.12.003","article-title":"Clinical outcome of ALK-positive non-small cell lung cancer (NSCLC) patients with de novo EGFR or KRAS co-mutations receiving tyrosine kinase inhibitors (TKIs)","volume":"12","author":"Schmid","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105574_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2025.105574_bib29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2025.105574_bib30","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:59:54Z","timestamp":1772895594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014437"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105574","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105574"}}